PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital
17. November 2022 20:29 ET
|
PaxMedica, Inc.
-Agreement Provides Flexible Funding on Path to NDA Submission for PAX-101- TARRYTOWN, NY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage...
PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results
15. November 2022 08:00 ET
|
PaxMedica, Inc.
-PXMD Strengthened Executive Team and Board of Directors With Recent Appointments After IPO in August 2022- -Phase 3 Results for HAT-301 Trial Expected in First Half 2023- TARRYTOWN, NY, Nov. 15,...
PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission
08. November 2022 08:00 ET
|
PaxMedica, Inc.
Final Study Results are Expected in First Half of 2023 TARRYTOWN, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical...
PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer
24. Oktober 2022 08:00 ET
|
PaxMedica, Inc.
Dr. Schwabe brings 30+ years of Clinical Experience in the Pharmaceutical Industry TARRYTOWN, NY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a...
PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento to Its Board of Directors
03. Oktober 2022 08:00 ET
|
PaxMedica, Inc.
Founder of several public life sciences companies including Questcor, Osteologix and Indevus, Casamento will serve as an Independent Director TARRYTOWN, NY, Oct. 03, 2022 (GLOBE NEWSWIRE) -- via...
PaxMedica, Inc. Provides Corporate Update After IPO
27. September 2022 08:00 ET
|
PaxMedica, Inc.
-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer- -Second Independent Director, Dr. John F. Coelho, Appointed to Board of Directors in May...
PaxMedica, Inc. Announces Pricing of Initial Public Offering
26. August 2022 08:00 ET
|
PaxMedica, Inc.
Shares will Trade on Nasdaq Capital Market under Ticker Symbol “PXMD” TARRYTOWN, NY, Aug. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage...
PaxMedica Receives FDA Orphan Drug Designation for Use of PAX-101 (IV suramin) in a Rare Tropical Disease
02. Februar 2021 08:30 ET
|
PaxMedica, Inc.
Company Pursuing Development of PAX-101 as Treatment for Autism Spectrum Disorder and Other Neurodevelopmental Conditions WOODCLIFF LAKE, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --...